Wonbiogen원바이오젠
307280 · KOSDAQ · ₩307280 · 원바이오젠
₩5,500▼ ₩120 (2.14%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩35B | ₩30B | ₩30B | ₩27B | ₩18B |
| Cost of sales | ₩17B | ₩16B | ₩15B | ₩14B | ₩10B |
| Gross profit | ₩18B | ₩14B | ₩14B | ₩12B | ₩7.6B |
| Operating income | ₩7.9B | ₩6.4B | ₩7.1B | ₩5.2B | ₩2B |
| Net income | ₩6.5B | ₩5.3B | ₩6B | ₩3.3B | −₩660M |
| Net income to shareholders | ₩6.6B | ₩5.7B | ₩5.5B | ₩3.3B | −₩660M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩48B | ₩41B | ₩43B | ₩39B | ₩38B |
| Current assets | ₩27B | ₩22B | ₩21B | ₩18B | ₩23B |
| Cash and equivalents | ₩8.3B | ₩7.2B | ₩3B | ₩3.2B | ₩7.7B |
| Total liabilities | ₩5B | ₩4B | ₩10B | ₩12B | ₩11B |
| Current liabilities | ₩4.5B | ₩3.3B | ₩9.3B | ₩12B | ₩11B |
| Borrowings | ₩367M | ₩617M | ₩6.8B | ₩758M | ₩831M |
| Total equity | ₩43B | ₩37B | ₩33B | ₩27B | ₩27B |
| Shareholders' equity | ₩43B | ₩37B | ₩32B | ₩27B | ₩27B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩8.5B | ₩8.8B | ₩4.8B | ₩5.8B | ₩1.1B |
| Capital spending | ₩2B | ₩648M | ₩1.6B | ₩6.5B | ₩2.3B |
| Free cash flow | ₩6.5B | ₩8.2B | ₩3.2B | −₩712M | −₩1.3B |
| Dividends paid | ₩709M | ₩709M | ₩350M | — | — |
Consolidated where available. Amounts in won.
Also known as: Wonbiogen / 원바이오젠 / 307280 / KRX:307280
Source: KRX statistical information